Ventrus Biosciences, Inc.  (VTUS) Receives SPA Response From FDA and Will Update and File the First Pivotal Trial Protocol to its IND  
6/22/2011 9:21:05 AM

NEW YORK, June 22, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it has received a response from the U.S. Food and Drug Administration (FDA) to its last Special Protocol Assessment (SPA) submission for iferanserin (VEN 309) for the treatment of hemorrhoids, and will update the protocol for the company's first pivotal trial for iferanserin and file it to its investigational new drug application (IND), so that the trial can start as planned.